Medicare Finalizes 2.48% Rate Hike

Watch on YouTube ↗  |  April 06, 2026 at 21:05  |  2:39  |  Bloomberg Markets

Summary

  • The Trump administration initially proposed a 0% rate increase for Medicare Advantage payments in the 2027 budget to control healthcare costs, causing a significant market sell-off.
  • Major private insurers threatened to exit the Medicare Advantage market, citing insufficient payments to cover rising costs, which created pressure on the government.
  • The government revised the final payment rate increase to 2.48% for 2027, a meaningful improvement over the initial proposal.
  • The final rate, while a "significant drop" from the ~6% increase of the previous year, was far better than the worst-case expectation of 0% and exceeded investor hopes for 1-1.5%.
  • This outcome is a "huge boon for investors" as it is "all about expectations"; the positive surprise is driving immediate stock gains.
  • Companies that stayed in the Medicare Advantage space, like UnitedHealth, Humana, and CVS, are seeing immediate benefits and are expected to reap gains for the foreseeable future.
  • A key uncertainty is long-term policy: CMS administrator Chris Clump expects these programs to dial back costs, but moving too quickly could cause insurers to pull out again.
  • The immediate implication is a relief rally for managed care stocks heavily exposed to Medicare Advantage, reversing the negative sentiment from January.
Trade Ideas
Michelle Cortez Bloomberg Reporter 1:52
The speaker explicitly stated UnitedHealth's stock was "going through the roof today" following the announcement of a 2.48% Medicare Advantage rate increase for 2027. The final rate was much better than the 0% initially feared, representing a positive expectation shock. Companies that remained in the Medicare Advantage market are positioned to benefit. LONG because the company is a direct, immediate beneficiary of the favorable rate decision, which secures its profitability in a key business line for the near term. Future administration policy aimed at aggressively dialing back program costs could pressure margins and lead to strategic pullbacks.
Michelle Cortez Bloomberg Reporter 1:52
The speaker explicitly stated "Humana is benefiting" following the announcement of the improved Medicare Advantage rate hike. Humana, as a major player in Medicare Advantage, faced significant downside risk from a 0% rate increase. The final 2.48% hike alleviates that pressure and improves the earnings outlook. LONG as the company is named a direct beneficiary of the positive regulatory development, which supports its core business model. The company's heavy exposure to Medicare Advantage makes it vulnerable to any future regulatory attempts to curtail payment growth more severely.
Michelle Cortez Bloomberg Reporter 1:52
The speaker explicitly listed CVS among the "big insurance companies" benefiting from the Medicare Advantage rate decision. CVS (via its Aetna business) is a significant participant in the Medicare Advantage market. The better-than-feared rate hike removes a major overhang on the profitability of this segment. LONG because the company is identified as a winner from the policy reversal, which should support its integrated health services model. Similar to peers, the long-term risk is regulatory pressure to reduce costs within the Medicare Advantage program.
Up Next

This Bloomberg Markets video, published April 06, 2026, features Michelle Cortez discussing UNH, HUM, CVS. 3 trade ideas extracted by AI with direction and confidence scoring.

Speakers: Michelle Cortez  · Tickers: UNH, HUM, CVS